The Medical University of Vienna's Core Facilities secured €2.5 million from the Austrian Research Promotion Agency to advance multiomics-based biomarker discovery and validation. The funding supports acquisition of technologies for single-cell analyses, mass spectrometry, and volumetric imaging. This initiative, named Moonshot, aims to accelerate translational precision medicine by enabling rapid identification of disease-relevant biomarkers suitable for clinical application.